The most serious side effects are
- a reduction in the number of immune cells,
- liver failure,
- serious opportunistic infections (for example, fungal infections),
- cancer and
- allergic reactions.
Alefacept should not be used by individuals whose blood lymphocyte counts are less than 250/ml.
GENERIC AVAILABLE: No
PREPARATIONS: Powder for Injection: 15 mg/Vial for intramuscular use.
STORAGE: Alefacept should be stored at room temperature, 15 C to 30 C (59 C to 86 F).
DOSING: The recommended dose is 15 mg by intramuscular injection once weekly for 12 weeks. The treatment cycle can be repeated after a twelve week interval without treatment if the patient's T-lymphocyte counts are within the normal range.
DRUG INTERACTIONS: Alefacept suppresses the immune system. It should not be used with other drugs the also suppress the immune system because this will add to the risk of developing serious infections. Safety and efficacy of receiving live or weakened (attenuated) vaccines during alefacept treatment has not been evaluated.
PREGNANCY: Use of alefacept during pregnancy has not been evaluated.
NURSING MOTHERS: Use of alefacept by nursing mothers has not been adequately evaluated. It is not known whether alefacept is excreted in breast milk.
Medically reviewed by Eni Williams, PharmD
Reference: FDA Prescribing Information
Quick GuidePsoriasis Types, Images, Treatments
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Need help identifying pills and medications?
Use the pill identifier tool on RxList.